MAPT and Down syndrome: In the current study, we examined the age “inflection point” at which MRI-based cerebrovascular disease markers emerge in adults with Down syndrome, characterizing them relative to the temporality of amyloid and tau biomarkers, measured with positron emission tomography (PET).